Combined gastrin releasing peptide-29 and glucagon like peptide-1 reduce body weight more than each individual peptide in diet-induced obese male rats

Recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over the last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in their ability to improve glycaemia, reduce body weight and in their cardio- and renal protective potentials. Understanding how these agents work, including insights into their pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, their clinical effects and mode of actions, and we offer insights into the potential of GLP-1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.

Download Full-text

The Kv1.3 channel blocker Vm24 enhances muscle glucose transporter 4 mobilization but does not reduce body-weight gain in diet-induced obese male rats

Life Sciences ◽

10.1016/j.lfs.2017.05.027 ◽

2017 ◽

Vol 181 ◽

pp. 23-30 ◽

Cited By ~ 3

Author(s):

Lorraine Jaimes-Hoy ◽

Georgina B. Gurrola ◽

Miguel Cisneros ◽

Patricia Joseph-Bravo ◽

Lourival D. Possani ◽

...

Keyword(s):

Body Weight ◽

Weight Gain ◽

Glucose Transporter ◽

Channel Blocker ◽

Body Weight Gain ◽

Male Rats ◽

Glucose Transporter 4 ◽

Reduce Body Weight ◽

Kv1.3 Channel ◽

Obese Male

Download Full-text

No Change in Serum Incretins Levels but Rise of Leptin Levels After Smoking Cessation: a Pilot Study

Physiological Research ◽

10.33549/physiolres.933154 ◽

2016 ◽

pp. 651-659 ◽

Cited By ~ 7

Author(s):

A. PANKOVA ◽

E. KRALIKOVA ◽

P. KAVALKOVA ◽

L. STEPANKOVA ◽

K. ZVOLSKA ◽

...

Keyword(s):

Smoking Cessation ◽

Body Weight ◽

Peptide Yy ◽

Gastric Inhibitory Polypeptide ◽

Male Adult ◽

Liquid Meal ◽

Quit Smoking ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Obese Male

The mechanisms behind the changes of body weight after smoking cessation are only partially understood. To this end, we explored the possible effects of smoking cessation on incretin hormones, leptin and selected anthropometric, biochemical and other hormonal parameters. Twenty-two non-obese male adult smokers attending an ambulatory smoking cessation program in Prague, Czech Republic, were examined at the baseline. Thirteen patients (mean age 37.92±2.66 years, mean body mass index 25.56±0.69 kg/m2) successfully quit smoking and were examined three months after smoking cessation; relapsed smokers were not followed up. The patients underwent 2-h liquid meal test with Fresubin and repeated blood sampling for measurements of blood glucose, gastric inhibitory polypeptide (GIP), glucagon-like peptide 1 (GLP-1), amylin, insulin, leptin, peptide-YY (PYY) and pancreatic polypeptide (PP). Three months after smoking cessation, body weight increased (4.35±3.32 kg, p<0.001). Leptin levels increased significantly in all repeated samples, while levels of GIP, GLP-1, amylin, insulin, PYY and PP remained unchanged. In conclusions, smoking cessation increased leptin levels probably owing to weight gain while it did not influence incretin levels.

Download Full-text

Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis

Journal of Psychopharmacology ◽

10.1177/02698811211035391 ◽

2021 ◽

pp. 026988112110353

Author(s):

Yewei Wang ◽

Dandan Wang ◽

Jie Cheng ◽

Xinyu Fang ◽

Yan Chen ◽

...

Keyword(s):

Body Weight ◽

Atypical Antipsychotics ◽

Randomized Clinical Trials ◽

Weighted Mean Difference ◽

Meta Analysis ◽

Metabolic Disturbance ◽

Pharmacological Interventions ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Meta Analyses

Background: There have been a few systematic reviews and conventional meta-analyses reporting effect of drugs on metabolic disturbance induced by atypical antipsychotics (AAPs). However, few of them provided sufficient and comprehensive comparisons between pharmacological interventions. Aims: We aimed to qualitatively compare drugs’ effect on AAPs-induced metabolic abnormalities by using network meta-analysis (NMA). Methods: We searched PubMed, EMBASE, Web of Science, Cochrane Controlled Register of Trials (CENTRAL), and PsycINFO on March 26, 2019. Of 5889 records identified, 61 randomized clinical trials including 3467 participants were included. We estimated weighted mean difference (WMD) and odds ratio (OR) using NMA. We assessed the risk of bias of individual studies with the Review Manager 5.3. Primary outcomes included change of body weight and body mass index (BMI). Secondary outcomes included change of other cardiometabolic risk factors, acceptability, and tolerability. Results: For body weight, topiramate (WMD −5.4, 95% CI −7.12 to −3.68), zonisamide (−3.44, 95% CI −6.57 to −0.36), metformin (−3.01, 95% CI −4.22 to −1.83), glucagon-like peptide-1 receptor agonists (GLP-1RAs) (−3.23, 95% CI −5.47 to −0.96), and nizatidine (−2.14, 95% CI −4.01 to −0.27) were significantly superior to placebo. Results regarding to BMI were similar to that of body weight. With respect to tolerability, only topiramate (OR 24, 95% CI 3.15 to 648) was inferior to placebo. Conclusions: Considering both efficacy and tolerability, evidence from this NMA indicates zonisamide, metformin, GLP-1RAs, and nizatidine in adults should be the first-line treatment for alleviating AAPs-induced weight gain or elevated BMI.

Download Full-text

10-OR: In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out

Diabetes ◽

10.2337/db21-10-or ◽

2021 ◽

Vol 70 (Supplement 1) ◽

pp. 10-OR

Author(s):

EMILIE S. ANDERSEN ◽

SIGNE FOGHSGAARD ◽

LOUISE VEDTOFTE ◽

MARIE H. PEDERSEN ◽

JULIE FORMAN ◽

...

Keyword(s):

Diabetes Mellitus ◽

Weight Loss ◽

Body Weight ◽

Gestational Diabetes ◽

Glucose Tolerance ◽

Gestational Diabetes Mellitus ◽

Receptor Agonist ◽

Body Weight Loss ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities

Problems of Endocrinology ◽

10.14341/probl201258351-55 ◽

2012 ◽

Vol 58 (3) ◽

pp. 51-55

Author(s):

E N Ostroukhova ◽

O K Khmel'nitskiĭ ◽

E I Krasil'nikova ◽

K S Davidenko

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Body Weight ◽

Adverse Reactions ◽

Brand Name ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Long Acting

This paper reports the results of the treatment of 71 patients presenting with type 2 diabetes mellitus using liraglutide, a long-acting analog of glucagon-like peptide-1 (GLP-1) marketed under the brand name Victoza. Practically all the patients experienced either improvement or normalization of the parameters of carbohydrate metabolism in conjunction with a reduction of their body weight and arterial pressure. There were no severe hypoglycemic episodes and other adverse reactions to the therapy. It is recommended that Victoza should be more widely used for the treatment of the patients with type 2 diabetes mellitus.

Download Full-text